05Jun/13

US Food and Drug Administration Approves REVLIMID® (lenalidomide) for the … – Fort Mills Times

US Food and Drug Administration Approves REVLIMID® (lenalidomide) for the
Fort Mills Times
approval was based on the results of MCL-001, a phase II, multi-center, single arm, open label study evaluating lenalidomide in 134 patients with MCL who had received prior treatment with rituximab, cyclophosphamide, an anthracycline (or

and more »

03Jun/13

Under One Roof: Roche Talks Up In-House Advantages In Cancer – The IN VIVO Blog (blog)


The IN VIVO Blog (blog)

Under One Roof: Roche Talks Up In-House Advantages In Cancer
The IN VIVO Blog (blog)
That’s what Roche is looking to do in hematology, moving from the rituximab base to new drugs like GA101. “We have a number of scenarios that can help us both extend the franchise and potentially replace and extend the franchise,” Roche Pharma COO